Author

Ambrogio Orlando

EFFECTIVENESS AND SAFETY OF ON-DEMAND FERRIC CARBOXYMALTOSE INFUSION STRATEGY FOR IRON DEFICIENCY ANEMIA IN INFLAMMATORY BOWEL DISEASE PATIENTS
EFFECTIVENESS AND SAFETY OF ON-DEMAND FERRIC CARBOXYMALTOSE INFUSION STRATEGY FOR IRON DEFICIENCY ANEMIA IN INFLAMMATORY BOWEL DISEASE PATIENTS

Ambrogio Orlando  et al.

SARCOPENIA IS A POOR PROGNOSTIC FACTOR FOR ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN’S DISEASE
SARCOPENIA IS A POOR PROGNOSTIC FACTOR FOR ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN’S DISEASE

Ambrogio Orlando  et al.

REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY
REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY

Ambrogio Orlando  et al.

BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN’S PATIENTS ON BIOLOGICS: A PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES
BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN’S PATIENTS ON BIOLOGICS: A PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES

Ambrogio Orlando  et al.

BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS
BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

Ambrogio Orlando  et al.

DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE
DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE

Ambrogio Orlando  et al.

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN BIOLOGIC-NAïVE PATIENTS: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN BIOLOGIC-NAïVE PATIENTS: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)

Ambrogio Orlando  et al.

VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE
VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE

Ambrogio Orlando  et al.

SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)

Ambrogio Orlando  et al.

EFFECTIVENESS OF USTEKINUMAB ON CROHN´S DISEASE ASSOCIATED SPONDYLOARTROPATHY
EFFECTIVENESS OF USTEKINUMAB ON CROHN´S DISEASE ASSOCIATED SPONDYLOARTROPATHY

Ambrogio Orlando  et al.

SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)
SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Ambrogio Orlando  et al.

SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS
SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS

Ambrogio Orlando  et al.

SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501
SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

Ambrogio Orlando  et al.

REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY
REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY

Ambrogio Orlando  et al.

Item 1 - 14 / 14
1